VANCOMYCIN
Report
- Report Number
- 1823260-2019-02299
- Event Type
- Malfunction
- Date Received
- June 25, 2019
- Date of Event
- May 18, 2019
- Report Date
- August 8, 2019
- Manufacturer
- ROCHE DIAGNOSTICS
- Product Code
- LEH
- PMA / PMN Number
- K060586
- Removal / Correction Number
- NA
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- BE
- Reporter Occupation
- OTHER HEALTH CARE PROFESSIONAL
Narratives
UPON INVESTIGATION OF THE PATIENT SAMPLES, IT WAS DETERMINED THAT THE SAMPLES CONTAIN AN INTERFERING SUBSTANCE WHICH INCREASES THE KINETICS OF THE AGGLUTINATION REACTION. FURTHER ANALYSIS OF THE SAMPLES BY SERUM ELECTROPHORESIS AND IMMUNFIXATION POINT TOWARD THE PRESENCE OF A MONO- OR BI-CLONAL LGM GAMMOPATHY OF A LAMBDA TYPE. PER PRODUCT LABELING, "IN VERY RARE CASES, GAMMOPATHY, IN PARTICULAR TYPE IGM (WALDENSTRÖM¿S MACROGLOBULINEMIA), MAY CAUSE UNRELIABLE RESULTS."
THIS EVENT OCCURRED IN (B)(6). THE 4 SAMPLES FROM THE PATIENT WERE SUBMITTED FOR INVESTIGATION. THE INVESTIGATION IS ONGOING.
THE INITIAL REPORTER COMPLAINED OF DISCREPANT LOW RESULTS FOR 4 SAMPLES FROM 1 PATIENT TESTED FOR ONLINE RDM VANCOMYCIN GEN. 3 (VANC3) ON A COBAS 8000 C 502 MODULE COMPARED TO THE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) METHOD AND THE ARCHITECT METHOD. THE PATIENT WAS IN THE HOSPITAL WITH A LUNG INFECTION WITH AN OXACILLIN RESISTANT S. AUREUS AND WAS ALREADY BEING TREATED WITH VANCOMYCIN. THE LOW RESULTS FROM THE C502 MODULE WERE REPORTED OUTSIDE OF THE LABORATORY WHERE THE PHYSICIAN INCREASED THE PATIENT'S VANCOMYCIN DOSAGE BASED ON THE RESULTS. THE PATIENT'S HEALTH WAS NOT NEGATIVELY AFFECTED BY THE HIGHER DOSAGE. THERE WAS NO ALLEGATION THAT AN ADVERSE EVENT OCCURRED DUE TO THE DEVICE RESULTS. THE C502 MODULE SERIAL NUMBER WAS (B)(4).
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 525986 | VANCOMYCIN | RADIOIMMUNOASSAY, VANCOMYCIN | LEH | ROCHE DIAGNOSTICS | NA | 391254 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 64 YR |